Glucose responsive insulin - AmideBio
Alternative Names: AB-GSI-084Latest Information Update: 28 Jan 2026
At a glance
- Originator AmideBio
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA
- 28 Jan 2026 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 22 Jan 2024 Glucose responsive insulin is still in preclinical trials for Type 1 diabetes mellitus and Type 2 diabetes mellitus in USA (AmideBio pipeline, January 2024)